DBVTechnologies

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
  • TickerDBV
  • ISINFR0010417345
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Withdrawal of the BLA application for Viaskin Peanut

>Withdrawal of the BLA application for Viaskin Peanut - We learned last night that that DBV had withdrawn its Biologics License Application (BLA) for its flagship Viaskin Peanut patch (feedback on 18 December). The application had been made for children aged 4 to 11. This decision comes after discussions with the US health authorities concerning manufacturing procedures and quality controls. According to the company’s press release, the BLA lacked “sufficient det...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Un retrait de sa demande d’autorisation de Viaskin Peanut

>Retrait de sa demande d’autorisation de Viaskin Peanut - Nous apprenons cette nuit que DBV avait retiré son dossier de demande d’autorisation de mise sur le marché de son patch phare Viaskin Peanut (retour le 18 décembre dernier). La demande d’enregistrement était faite chez les enfants âgés de 4 à 11 ans. Cette décision fait suite à des échanges avec les autorités de santé américaines concernant les procédures de fabrication et les contrôles de qualité du produ...

Hugo Solvet

DBV TECHNOLOGIES: Few details on resubmission timeline following BLA withdrawal | BUY | EUR46 vs. EUR100

DBV TECHNOLOGIES - BUY | EUR46 vs. EUR100 (+80%) Few details on resubmission timeline following BLA withdrawal BLA withdrawn on lack of CMC data The difference in between withdrawing and a RTF Timeline for resubmission unclear FV down to EUR46 as dilution risk now prevails

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Withdrawal of the BLA application for Viaskin Peanut

>Withdrawal of the BLA application for Viaskin Peanut - We learned last night that that DBV had withdrawn its Biologics License Application (BLA) for its flagship Viaskin Peanut patch (feedback on 18 December). The application had been made for children aged 4 to 11. This decision comes after discussions with the US health authorities concerning manufacturing procedures and quality controls. According to the company’s press release, the BLA lacked “sufficient det...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Un retrait de sa demande d’autorisation de Viaskin Peanut

>Retrait de sa demande d’autorisation de Viaskin Peanut - Nous apprenons cette nuit que DBV avait retiré son dossier de demande d’autorisation de mise sur le marché de son patch phare Viaskin Peanut (retour le 18 décembre dernier). La demande d’enregistrement était faite chez les enfants âgés de 4 à 11 ans. Cette décision fait suite à des échanges avec les autorités de santé américaines concernant les procédures de fabrication et les contrôles de qualité du produ...

Hugo Solvet

DBV TECHNOLOGIES: Few details on resubmission timeline following BLA withdrawal | BUY | EUR46 vs. EUR100

DBV TECHNOLOGIES - BUY | EUR46 vs. EUR100 (+80%) Few details on resubmission timeline following BLA withdrawal BLA withdrawn on lack of CMC data The difference in between withdrawing and a RTF Timeline for resubmission unclear FV down to EUR46 as dilution risk now prevails

1 director sold

A director at Dbv Technologies sold 30,000 shares at 33.090EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Martial Descoutures ...
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 12/20/2018

...

Martial Descoutures ...
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 20/12/2018

...

Charles Lepetitpas ...
  • Emmanuel Matot
  • Nicolas David
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/22/2018

...

Charles Lepetitpas ...
  • Emmanuel Matot
  • Nicolas David
  • Olfa Taamallah
  • Oussema Denguir
  • Pierre Corby
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 22/10/2018

...

DBV TECHNOLOGIES sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DBV TECHNOLOGIES (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date October 5, 2018, the closing price was EUR 33.50 and its target price was estimated at EUR 23.38.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

DBV Technologies SA (DBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform is an electrostatic patch that provides a suitable, self-administered and non-invasive immunotherapy to patients. DBV’s products include Viaskin Peanut for the treatment of peanut allergies; Viaskin Milk for cow’s protein milk allergies; Viaskin Egg for the treatment of egg allergy and Viaskin Pla...

Jehanne Leroy

Proxy Report - 22/06/2018

La société propose un vote sur les politiques de rémunérations 2018 des dirigeants (résolutions 16 à 18). Cependant, elle ne présente pas les montants en jeu pour ledit exercice, rendant ainsi impossible toute estimation des montants totaux en jeu ou de la structure de rémunération mise en place par la société. De la même façon, la société propose d'approuver les rémunérations 2017 de ses dirigeants mais ne communique ni la nature des indicateurs utilisés dans le cadre du calcul du bonus annuel ni leurs taux de réalisation individuels, rendant impossible pour l'actionnaire de comprendre comme...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Jérôme VINERIER

Analyse moyen terme - DBV TECHNOLOGIES : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 28,40 €, puis 21,60 €. Le franchissement de 47,40 € remettrait en cause la suite de la baisse.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch